Related Experiment Video
Updated: Dec 8, 2025

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective
Published on: January 12, 2024
The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle
Guillermo Carvajal Alegria1, Sara Boukhlal2, Divi Cornec1
1Univ Brest, Inserm, CHU de Brest, LBAI, UMR1227, Brest, France; Service de Rhumatologie, Centre de Référence Maladies Autoimmunes Rares CERAINO, CHU Cavale Blanche, Brest, France.
Abstract:
Polymyalgia rheumatica (PMR) is a frequent rheumatic condition among people over 50 years of age. Despite its frequent association with giant cell arteritis (GCA), PMR can be isolated. Its pathophysiology is poorly understood. Nevertheless, many studies are ongoing; 98 studies are currently referenced in ClinicalTrials.org involving several conventional and targeted therapies. In this review, we synthetize the current knowledge about PMR pathophysiology according to genetic and immunogenetic, immunologic, antibody and aging data. Immunogenetic data are mainly related to the HLA system and the association between the HLA-DRB1 and PMR. Few studies are also about immunogenetics of proinflammatory interleukins (i.e. IL-6). The decrease of CD8+Tcells and the strong increase of IL-6 where the main elements of PMR's pathophysiology until the recent years. The disturbance of B cell homeostasis, the search for IL-6 secretion by the innate immune system, the role of aging, are new elements revealed by recent studies. Aging might be a key element to consider as PMR occurs in patients over 50 years of age. Aging may act by the increased susceptibility to infections, by immunological modifications or hormonal disturbances. The role of the cellular infiltration around the joints remains a crucial question. Only a handful of studies described this infiltration. Finally, this review reveals the gaps in available data and suggests new leads and in-depth studies for further research on PMR pathophysiology.
Insights
Polymyalgia rheumatica (PMR) is a common condition in those over 50. Recent research highlights aging, B cell changes, and IL-6
Area of Science:
- Rheumatology
- Immunology
- Gerontology
Background:
- Polymyalgia rheumatica (PMR) is a prevalent rheumatic disease affecting individuals over 50.
- While often linked to giant cell arteritis (GCA), PMR can occur independently.
- The underlying pathophysiology of PMR remains incompletely understood.
Purpose of the Study:
- To synthesize current knowledge on PMR pathophysiology.
- To review data from genetic, immunogenetic, immunologic, antibody, and aging studies.
- To identify gaps in current understanding and suggest future research directions.
Main Methods:
- Literature review of existing studies on PMR pathophysiology.
- Analysis of data related to genetics (HLA system, HLA-DRB1), immunogenetics (interleukins like IL-6), and immunology (CD8+ T cells, B cell homeostasis).
- Inclusion of recent findings on the role of aging and cellular infiltration.
Main Results:
- Established associations include the HLA-DRB1 gene and elevated IL-6 levels.
- Recent studies reveal the significance of B cell homeostasis disturbances and IL-6 secretion by the innate immune system.
- Aging emerges as a critical factor, potentially influencing susceptibility to infections, immune modulation, and hormonal changes.
Conclusions:
- PMR pathophysiology involves complex interactions including genetic predisposition, immune dysregulation, and the aging process.
- Further research is needed to elucidate the role of cellular infiltration around joints.
- Understanding these factors is crucial for developing effective therapeutic strategies for PMR.
More Related Videos
12:23Flow Cytometry Analysis of Immune Cell Subsets within the Murine Spleen, Bone Marrow, Lymph Nodes and Synovial Tissue in an Osteoarthritis Model
Published on: April 24, 2020
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Myocarditis I: Introduction
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy IV: Restrictive Cardiomyopathy